Skip Navigation


Nucleic Acids Research Advance Access originally published online on January 31, 2007
Nucleic Acids Research 2007 35(5):e34; doi:10.1093/nar/gkl1152
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (520K) Freely available
Right arrow Screen PDF (301K) Freely available
Right arrow Supplementary Material
Right arrowOA All Versions of this Article:
35/5/e34    most recent
gkl1152v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Milani, L.
Right arrow Articles by Syvänen, A.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milani, L.
Right arrow Articles by Syvänen, A.-C.
Related Collections
Right arrow Polymorphism/mutation detection
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2007, Vol. 35, No. 5 e34
© 2007 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Methods Online

Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells

Lili Milani1, Manu Gupta1, Malin Andersen3, Sumeer Dhar2, Mårten Fryknäs2, Anders Isaksson2, Rolf Larsson2 and Ann-Christine Syvänen1,*

1Molecular Medicine, 2Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden and 3Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology (KTH), Stockholm, Sweden

*To whom correspondence should be addressed. Tel: +46 18 6112959; Fax: +46 18 553601; E-mail: Ann-Christine.Syvanen{at}medsci.uu.se

Received November 3, 2006. Revised December 6, 2006. Accepted December 6, 2006.

Using the relative expression levels of two SNP alleles of a gene in the same sample is an effective approach for identifying cis-acting regulatory SNPs (rSNPs). In the current study, we established a process for systematic screening for cis-acting rSNPs using experimental detection of AI as an initial approach. We selected 160 expressed candidate genes that are involved in cancer and anticancer drug resistance for analysis of AI in a panel of cell lines that represent different types of cancers and have been well characterized for their response patterns against anticancer drugs. Of these genes, 60 contained heterozygous SNPs in their coding regions, and 41 of the genes displayed imbalanced expression of the two cSNP alleles. Genes that displayed AI were subjected to bioinformatics-assisted identification of rSNPs that alter the strength of transcription factor binding. rSNPs in 15 genes were subjected to electrophoretic mobility shift assay, and in eight of these genes (APC, BCL2, CCND2, MLH1, PARP1, SLIT2, YES1, XRCC1) we identified differential protein binding from a nuclear extract between the SNP alleles. The screening process allowed us to zoom in from 160 candidate genes to eight genes that may contain functional rSNPs in their promoter regions.


Present addresses: Manu Gupta, Cancer Research UK Medical Oncology Laboratory, Barts and the Royal London School of Medicine, Queen Mary College, London, UK

Sumeer Dhar, Department of Pharmacogenomics and Experimental Therapeutics, UNC School of Pharmacy, Chapel Hill, NC, USA


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
A. Ameur, A. Rada-Iglesias, J. Komorowski, and C. Wadelius
Identification of candidate regulatory SNPs by combination of transcription-factor-binding site prediction, SNP genotyping and haploChIP
Nucleic Acids Res., May 18, 2009; (2009) gkp381v1.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
Y. Kakuta, N. Ueki, Y. Kinouchi, K. Negoro, K. Endo, E. Nomura, S. Takagi, S. Takahashi, and T. Shimosegawa
TNFSF15 transcripts from risk haplotype for Crohn's disease are overexpressed in stimulated T cells
Hum. Mol. Genet., March 15, 2009; 18(6): 1089 - 1098.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. O'Shea, C. O'Riain, M. Gupta, R. Waters, Y. Yang, D. Wrench, J. Gribben, A. Rosenwald, G. Ott, L. M. Rimsza, et al.
Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation
Blood, March 5, 2009; 113(10): 2298 - 2301.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
L. Milani, A. Lundmark, J. Nordlund, A. Kiialainen, T. Flaegstad, G. Jonmundsson, J. Kanerva, K. Schmiegelow, K. L. Gunderson, G. Lonnerholm, et al.
Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation
Genome Res., January 1, 2009; 19(1): 1 - 11.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
L. P. Jordheim, T. Nguyen-Dumont, X. Thomas, C. Dumontet, and S. V. Tavtigian
Differential Allelic Expression in Leukoblast from Patients with Acute Myeloid Leukemia Suggests Genetic Regulation of CDA, DCK, NT5C2, NT5C3, and TP53
Drug Metab. Dispos., December 1, 2008; 36(12): 2419 - 2423.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.